Quarterly report · Q1
9987.TEDINET S100RMWL
Period2023-04-01 → 2023-06-30
Filed2023-08-14
StandardJapan GAAP
ConsolidatedYes
Data checks12 of 12 passed
Key figures · 31
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥573.6bn | 2023-04-01 → 2023-06-30 | Cons. | Net sales |
| Revenue | ¥2.31T | 2022-04-01 → 2023-03-31 | Cons. | Net sales (5-year summary) |
| Revenue | ¥553.8bn | 2022-04-01 → 2022-06-30 | Cons. | Net sales |
| Operating income | ¥4.1bn | 2023-04-01 → 2023-06-30 | Cons. | Operating income |
| Operating income | ¥3.5bn | 2022-04-01 → 2022-06-30 | Cons. | Operating income |
| Ordinary income | ¥5.0bn | 2023-04-01 → 2023-06-30 | Cons. | Ordinary income |
| Ordinary income | ¥36.4bn | 2022-04-01 → 2023-03-31 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥4.6bn | 2022-04-01 → 2022-06-30 | Cons. | Ordinary income |
| Profit before tax | ¥5.1bn | 2023-04-01 → 2023-06-30 | Cons. | Income before income taxes |
| Profit before tax | ¥4.5bn | 2022-04-01 → 2022-06-30 | Cons. | Income before income taxes |
| Net income (owners) | ¥3.3bn | 2023-04-01 → 2023-06-30 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥20.3bn | 2022-04-01 → 2023-03-31 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥2.7bn | 2022-04-01 → 2022-06-30 | Cons. | Profit loss attributable to owners of parent |
| Net income | ¥3.3bn | 2023-04-01 → 2023-06-30 | Cons. | Profit loss |
| Net income | ¥2.7bn | 2022-04-01 → 2022-06-30 | Cons. | Profit loss |
| Total assets | ¥1.19T | at 2023-06-30 | Cons. | Assets |
| Total assets | ¥1.15T | at 2023-03-31 | Cons. | Assets |
| Total assets | ¥1.17T | at 2022-06-30 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥772.0bn | at 2023-06-30 | Cons. | Liabilities |
| Total liabilities | ¥734.6bn | at 2023-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥418.1bn | at 2023-06-30 | Cons. | Net assets |
| Net assets / equity | ¥411.5bn | at 2023-03-31 | Cons. | Net assets |
| Net assets / equity | ¥419.3bn | at 2022-06-30 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥114.2bn | at 2023-06-30 | Cons. | Cash and deposits |
| Cash and deposits | ¥109.0bn | at 2023-03-31 | Cons. | Cash and deposits |
| EPS (basic) | ¥40.4 | 2023-04-01 → 2023-06-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥236.47 | 2022-04-01 → 2023-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥30.49 | 2022-04-01 → 2022-06-30 | Cons. | Basic earnings loss per share (5-year summary) |
| Equity ratio | 35.1% | at 2023-06-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 35.9% | at 2023-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 36.0% | at 2022-06-30 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 40
| Segment | Item | Period | Value |
|---|---|---|---|
| jpcrp040300-q1r_E02780-000The Community Healthcare And Nursing Care Support Businessreportable segment | revenue | 2023-04-01 → 2023-06-30 | ¥23.9bn |
| jpcrp040300-q1r_E02780-000The Community Healthcare And Nursing Care Support Businessreportable segment | revenue external | 2023-04-01 → 2023-06-30 | ¥23.9bn |
| jpcrp040300-q1r_E02780-000The Community Healthcare And Nursing Care Support Businessreportable segment | revenue intersegment | 2023-04-01 → 2023-06-30 | ¥3m |
| jpcrp040300-q1r_E02780-000The Community Healthcare And Nursing Care Support Businessreportable segment | segment profit | 2023-04-01 → 2023-06-30 | −¥38m |
| jpcrp040300-q1r_E02780-000The Healthcare Product Development Businessreportable segment | revenue | 2023-04-01 → 2023-06-30 | ¥12.8bn |
| jpcrp040300-q1r_E02780-000The Healthcare Product Development Businessreportable segment | revenue external | 2023-04-01 → 2023-06-30 | ¥2.9bn |
| jpcrp040300-q1r_E02780-000The Healthcare Product Development Businessreportable segment | revenue intersegment | 2023-04-01 → 2023-06-30 | ¥9.9bn |
| jpcrp040300-q1r_E02780-000The Healthcare Product Development Businessreportable segment | segment profit | 2023-04-01 → 2023-06-30 | ¥521m |
| jpcrp040300-q1r_E02780-000The Healthcare Related Services Businessreportable segment | revenue | 2023-04-01 → 2023-06-30 | ¥63.8bn |
| jpcrp040300-q1r_E02780-000The Healthcare Related Services Businessreportable segment | revenue external | 2023-04-01 → 2023-06-30 | ¥7.1bn |
| jpcrp040300-q1r_E02780-000The Healthcare Related Services Businessreportable segment | revenue intersegment | 2023-04-01 → 2023-06-30 | ¥56.7bn |
| jpcrp040300-q1r_E02780-000The Healthcare Related Services Businessreportable segment | segment profit | 2023-04-01 → 2023-06-30 | ¥213m |
| jpcrp040300-q1r_E02780-000The Pharmaceutical Distribution Businessreportable segment | revenue | 2023-04-01 → 2023-06-30 | ¥553.4bn |
| jpcrp040300-q1r_E02780-000The Pharmaceutical Distribution Businessreportable segment | revenue external | 2023-04-01 → 2023-06-30 | ¥539.8bn |
| jpcrp040300-q1r_E02780-000The Pharmaceutical Distribution Businessreportable segment | revenue intersegment | 2023-04-01 → 2023-06-30 | ¥13.7bn |
| jpcrp040300-q1r_E02780-000The Pharmaceutical Distribution Businessreportable segment | segment profit | 2023-04-01 → 2023-06-30 | ¥3.3bn |
| Total Of Reportable Segments And Otherssegment total | revenue | 2023-04-01 → 2023-06-30 | ¥653.9bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2023-04-01 → 2023-06-30 | ¥573.6bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2023-04-01 → 2023-06-30 | ¥80.3bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2023-04-01 → 2023-06-30 | ¥4.0bn |
| jpcrp040300-q1r_E02780-000The Community Healthcare And Nursing Care Support Businessreportable segment | revenue | 2022-04-01 → 2022-06-30 | ¥24.0bn |
| jpcrp040300-q1r_E02780-000The Community Healthcare And Nursing Care Support Businessreportable segment | revenue external | 2022-04-01 → 2022-06-30 | ¥24.0bn |
| jpcrp040300-q1r_E02780-000The Community Healthcare And Nursing Care Support Businessreportable segment | revenue intersegment | 2022-04-01 → 2022-06-30 | ¥0 |
| jpcrp040300-q1r_E02780-000The Community Healthcare And Nursing Care Support Businessreportable segment | segment profit | 2022-04-01 → 2022-06-30 | ¥198m |
| jpcrp040300-q1r_E02780-000The Healthcare Product Development Businessreportable segment | revenue | 2022-04-01 → 2022-06-30 | ¥11.8bn |
| jpcrp040300-q1r_E02780-000The Healthcare Product Development Businessreportable segment | revenue external | 2022-04-01 → 2022-06-30 | ¥3.2bn |
| jpcrp040300-q1r_E02780-000The Healthcare Product Development Businessreportable segment | revenue intersegment | 2022-04-01 → 2022-06-30 | ¥8.6bn |
| jpcrp040300-q1r_E02780-000The Healthcare Product Development Businessreportable segment | segment profit | 2022-04-01 → 2022-06-30 | ¥613m |
| jpcrp040300-q1r_E02780-000The Healthcare Related Services Businessreportable segment | revenue | 2022-04-01 → 2022-06-30 | ¥49.7bn |
| jpcrp040300-q1r_E02780-000The Healthcare Related Services Businessreportable segment | revenue external | 2022-04-01 → 2022-06-30 | ¥6.9bn |
| jpcrp040300-q1r_E02780-000The Healthcare Related Services Businessreportable segment | revenue intersegment | 2022-04-01 → 2022-06-30 | ¥42.7bn |
| jpcrp040300-q1r_E02780-000The Healthcare Related Services Businessreportable segment | segment profit | 2022-04-01 → 2022-06-30 | ¥242m |
| jpcrp040300-q1r_E02780-000The Pharmaceutical Distribution Businessreportable segment | revenue | 2022-04-01 → 2022-06-30 | ¥533.5bn |
| jpcrp040300-q1r_E02780-000The Pharmaceutical Distribution Businessreportable segment | revenue external | 2022-04-01 → 2022-06-30 | ¥519.6bn |
| jpcrp040300-q1r_E02780-000The Pharmaceutical Distribution Businessreportable segment | revenue intersegment | 2022-04-01 → 2022-06-30 | ¥13.8bn |
| jpcrp040300-q1r_E02780-000The Pharmaceutical Distribution Businessreportable segment | segment profit | 2022-04-01 → 2022-06-30 | ¥2.4bn |
| Total Of Reportable Segments And Otherssegment total | revenue | 2022-04-01 → 2022-06-30 | ¥618.9bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2022-04-01 → 2022-06-30 | ¥553.8bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2022-04-01 → 2022-06-30 | ¥65.2bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2022-04-01 → 2022-06-30 | ¥3.5bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 344
| Item | Context | Value | Unit |
|---|---|---|---|
| Net sales | CurrentYTDDuration_jpcrp040300-q1r_E02780-000TheHealthcareRelatedServicesBusinessReportableSegmentsMember | 63799000000 | JPY |
| Net sales | CurrentYTDDuration_TotalOfReportableSegmentsAndOthersMember | 653914000000 | JPY |
| Operating income | CurrentYTDDuration_jpcrp040300-q1r_E02780-000ThePharmaceuticalDistributionBusinessReportableSegmentsMember | 3349000000 | JPY |
| Operating income | CurrentYTDDuration_jpcrp040300-q1r_E02780-000TheHealthcareProductDevelopmentBusinessReportableSegmentMember | 521000000 | JPY |
| Operating income | CurrentYTDDuration_jpcrp040300-q1r_E02780-000TheCommunityHealthcareAndNursingCareSupportBusinessReportableSegmentMember | -38000000 | JPY |
| Operating income | CurrentYTDDuration_jpcrp040300-q1r_E02780-000TheHealthcareRelatedServicesBusinessReportableSegmentsMember | 213000000 | JPY |
| Operating income | CurrentYTDDuration_TotalOfReportableSegmentsAndOthersMember | 4045000000 | JPY |
| Document title cover page | FilingDateInstant | Original text (Japanese)四半期報告書 | |
| Clause of stipulation cover page | FilingDateInstant | Original text (Japanese)金融商品取引法第24条の４の７第１項 | |
| Place of filing cover page | FilingDateInstant | Original text (Japanese)関東財務局長 | |
| Filing date cover page | FilingDateInstant | 2023-08-14 | |
| Quarterly accounting period cover page | FilingDateInstant | Original text (Japanese)第78期 第１四半期(自 2023年４月１日 至 2023年６月30日) | |
| Company name cover page | FilingDateInstant | Original text (Japanese)株式会社スズケン | |
| Company name in english cover page | FilingDateInstant | SUZUKEN CO.,LTD. | |
| Title and name of representative cover page | FilingDateInstant | Original text (Japanese)代表取締役社長 浅野 茂 | |
| Address of registered headquarter cover page | FilingDateInstant | Original text (Japanese)名古屋市東区東片端町８番地 | |
| Telephone number address of registered headquarter cover page | FilingDateInstant | Original text (Japanese)052(961)2331（代表） | |
| Name of contact person address of registered headquarter cover page | FilingDateInstant | Original text (Japanese)経営管理部長 長縄 淳 | |
| Nearest place of contact cover page | FilingDateInstant | Original text (Japanese)名古屋市東区東片端町８番地 | |
| Telephone number nearest place of contact cover page | FilingDateInstant | Original text (Japanese)052(961)2331（代表） | |
| Name of contact person nearest place of contact cover page | FilingDateInstant | Original text (Japanese)経営管理部長 長縄 淳 | |
| Place for public inspection cover page (text) | FilingDateInstant | Text · Plus | |
| Edinet code | FilingDateInstant | E02780 | |
| Fund code | FilingDateInstant | － | |
| Security code | FilingDateInstant | 99870 | |
| Filer name in japanese | FilingDateInstant | Original text (Japanese)株式会社スズケン | |
| Filer name in english | FilingDateInstant | SUZUKEN CO.,LTD. | |
| Fund name in japanese | FilingDateInstant | － | |
| Fund name in english | FilingDateInstant | － | |
| Cabinet office ordinance | FilingDateInstant | Original text (Japanese)企業内容等の開示に関する内閣府令 | |
| Document type | FilingDateInstant | Original text (Japanese)第四号の三様式 | |
| Accounting standards | FilingDateInstant | Japan GAAP | |
| Whether consolidated financial statements are prepared | FilingDateInstant | true | |
| Industry code when consolidated financial statements are prepared in accordance with industry specific regulations | FilingDateInstant | cte | |
| Industry code when financial statements are prepared in accordance with industry specific regulations | FilingDateInstant | － | |
| Current fiscal year start date | FilingDateInstant | 2023-04-01 | |
| Current period end date | FilingDateInstant | 2023-06-30 | |
| Type of current period | FilingDateInstant | Q1 | |
| Current fiscal year end date | FilingDateInstant | 2024-03-31 | |
| Previous fiscal year start date | FilingDateInstant | 2022-04-01 | |
| Comparative period end date | FilingDateInstant | 2022-06-30 | |
| Previous fiscal year end date | FilingDateInstant | 2023-03-31 | |
| Next fiscal year start date | FilingDateInstant | － | |
| End date of quarterly or semi annual period of next fiscal year | FilingDateInstant | － | |
| Amendment flag | FilingDateInstant | false | |
| Identification of document subject to amendment | FilingDateInstant | － | |
| Report amendment flag | FilingDateInstant | false | |
| Xbrl amendment flag | FilingDateInstant | false | |
| Business results of group (text) | FilingDateInstant | Text · Plus | |
| Description of business (text) | FilingDateInstant | Text · Plus |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 12 of 12 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |